$DFCO
DALRADA FINANCIAL CORP Stock $dfco

$dfco Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000168316824000995 Filed on February 14, 2024

Income Statement

Concept	2024 Q1	2023 Q4
Revenue	$10.31M	$6.078M
YoY Change	8.77%	15.7%
Cost Of Revenue	$5.594M	$4.076M
YoY Change	-15.4%	37.93%
Gross Profit	$4.711M	$2.002M
YoY Change	64.62%	-12.89%
Gross Profit Margin	45.72%	32.94%
Selling, General & Admin	$7.001M	$6.227M
YoY Change	7.69%	-12.04%
% of Gross Profit	148.6%	311.1%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$170.7K	$127.8K
YoY Change	80.95%	0.0%
% of Gross Profit	3.62%	6.38%
Operating Expenses	$7.001M	$6.227M
YoY Change	7.69%	-12.04%
Operating Profit	-$2.290M	-$4.226M
YoY Change	-37.08%	-11.64%
Interest Expense	$347.3K	$214.0K
YoY Change	10.5%	-82.47%
% of Operating Profit
Other Income/Expense, Net	-$617.9K	-$1.215M
YoY Change	51.97%	-504.94%
Pretax Income	-$2.908M	-$5.440M
YoY Change	-28.13%	21.37%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$2.883M	-$5.406M
YoY Change	-28.39%	22.51%
Net Earnings / Revenue	-27.97%	-88.95%
Basic Earnings Per Share	-$0.03	-$0.06
Diluted Earnings Per Share	-$0.03	-$0.06
COMMON SHARES
Basic Shares Outstanding	90.39M shares	89.93M shares
Diluted Shares Outstanding	92.93M shares	89.96M shares

Balance Sheet

Concept	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$533.6K	$598.4K
YoY Change	-58.6%	-46.09%
Cash & Equivalents	$533.6K	$598.4K
Short-Term Investments
Other Short-Term Assets	$582.9K	$668.9K
YoY Change	72.54%	6.58%
Inventory	$2.753M	$2.570M
Prepaid Expenses
Receivables	$9.841M	$5.489M
Other Receivables	$1.263M	$1.240M
Total Short-Term Assets	$15.88M	$11.49M
YoY Change	23.81%	11.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.426M	$1.623M
YoY Change	1.56%	6.24%
Goodwill	$3.803M	$3.803M
YoY Change	-10.59%	-10.59%
Intangibles	$3.561M	$3.655M
YoY Change	-9.18%	-2.29%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$14.29M	$14.93M
YoY Change	-10.16%	1.43%
TOTAL ASSETS
Total Short-Term Assets	$15.88M	$11.49M
Total Long-Term Assets	$14.29M	$14.93M
Total Assets	$30.17M	$26.43M
YoY Change	5.01%	5.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.692M	$5.554M
YoY Change	23.8%	117.67%
Accrued Expenses	$1.132M	$920.2K
YoY Change	-34.12%	-73.54%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$1.733M	$439.6K
YoY Change	67.42%	-36.04%
Total Short-Term Liabilities	$10.56M	$14.18M
YoY Change	-63.53%	-48.09%
LONG-TERM LIABILITIES
Long-Term Debt	$2.919M	$7.284M
YoY Change	-78.74%	-22.89%
Other Long-Term Liabilities	$7.872M	$7.898M
YoY Change	-10.21%	1.05%
Total Long-Term Liabilities	$10.79M	$15.18M
YoY Change	-52.03%	-12.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.56M	$14.18M
Total Long-Term Liabilities	$10.79M	$15.18M
Total Liabilities	$21.35M	$29.36M
YoY Change	-58.5%	-34.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$154.8M	-$152.0M
YoY Change	15.99%	17.37%
Common Stock	$481.3K	$471.4K
YoY Change	11.62%	10.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.760M	-$3.020M
YoY Change
Total Liabilities & Shareholders Equity	$30.17M	$26.43M
YoY Change	5.01%	5.45%

Cashflow Statement

Concept	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$2.883M	-$5.406M
YoY Change	-28.39%	22.51%
Depreciation, Depletion And Amortization	$170.7K	$127.8K
YoY Change	80.95%	0.0%
Cash From Operating Activities	-$2.184M	-$1.720M
YoY Change	-57.7%	-53.57%
INVESTING ACTIVITIES
Capital Expenditures	-$26.58K	$200.9K
YoY Change	-19.14%	-64.24%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	$26.58K	-$200.9K
YoY Change	-36.68%	-59.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.139M	2.222M
YoY Change	-56.11%	-43.39%
NET CHANGE
Cash From Operating Activities	-2.184M	-1.720M
Cash From Investing Activities	26.58K	-200.9K
Cash From Financing Activities	2.139M	2.222M
Net Change In Cash	-18.67K	301.8K
YoY Change	-92.47%	-212.08%
FREE CASH FLOW
Cash From Operating Activities	-$2.184M	-$1.720M
Capital Expenditures	-$26.58K	$200.9K
Free Cash Flow	-$2.158M	-$1.920M
YoY Change	-57.94%	-54.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0000725394
CY2023Q3	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
	DFCO	Finite Lived Intangible Assets Additions FiniteLivedIntangibleAssetsAdditions		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-12641
	dei	Entity Registrant Name EntityRegistrantName	DALRADA FINANCIAL CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	WY
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	38-3713274
	dei	Entity Address Address Line1 EntityAddressAddressLine1	600 La Terraza Blvd.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Escondido
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92025
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	283-1253
	dei	Security12b Title Security12bTitle	Common Stock, $0.005 par value per share
	dei	Trading Symbol TradingSymbol	DFCO
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	90392109	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	598438	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	812806	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5488915	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4453104	usd
CY2023Q4	DFCO	Accounts Receivable Net Related Parties Current AccountsReceivableNetRelatedPartiesCurrent	928648	usd
CY2023Q2	DFCO	Accounts Receivable Net Related Parties Current AccountsReceivableNetRelatedPartiesCurrent	752348	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1240009	usd
CY2023Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	376604	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2569843	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2078692	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	668877	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1343491	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	11494730	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	9817045	usd
CY2023Q4	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	20141	usd
CY2023Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	41722	usd
CY2023Q4	DFCO	Longterm Receivables Related Parties LongtermReceivablesRelatedParties	1155479	usd
CY2023Q2	DFCO	Longterm Receivables Related Parties LongtermReceivablesRelatedParties	1173893	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1623011	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1476082	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3803147	usd
CY2023Q2	us-gaap	Goodwill Goodwill	3803147	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3654823	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3858086	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2714198	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2771854	usd
CY2023Q4	DFCO	Operating Lease Right Of Use Asset Related Party OperatingLeaseRightOfUseAssetRelatedParty	1960494	usd
CY2023Q2	DFCO	Operating Lease Right Of Use Asset Related Party OperatingLeaseRightOfUseAssetRelatedParty	2227286	usd
CY2023Q4	us-gaap	Assets Assets	26426023	usd
CY2023Q2	us-gaap	Assets Assets	25169115	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5554117	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5178897	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	920159	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1084008	usd
CY2023Q4	DFCO	Accounts Payable And Accrued Liabilities Related Parties Current AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent	5029683	usd
CY2023Q2	DFCO	Accounts Payable And Accrued Liabilities Related Parties Current AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent	547949	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	938823	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1337259	usd
CY2023Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	439562	usd
CY2023Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	439562	usd
CY2023Q4	DFCO	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	0	usd
CY2023Q2	DFCO	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	251605	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	757569	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	660394	usd
CY2023Q4	DFCO	Operating Lease Liability Current Related Party OperatingLeaseLiabilityCurrentRelatedParty	536265	usd
CY2023Q2	DFCO	Operating Lease Liability Current Related Party OperatingLeaseLiabilityCurrentRelatedParty	519791	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14176178	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10019465	usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	33893	usd
CY2023Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	48888	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	2414936	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	1011395	usd
CY2023Q4	DFCO	Notes Payable Related Parties Noncurrent1 NotesPayableRelatedPartiesNoncurrent1	4834971	usd
CY2023Q2	DFCO	Notes Payable Related Parties Noncurrent1 NotesPayableRelatedPartiesNoncurrent1	1648478	usd
CY2023Q4	DFCO	Contingent Consideration ContingentConsideration	4402394	usd
CY2023Q2	DFCO	Contingent Consideration ContingentConsideration	4285389	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2027911	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2160834	usd
CY2023Q4	DFCO	Operating Lease Liability Noncurrent Related Party OperatingLeaseLiabilityNoncurrentRelatedParty	1467407	usd
CY2023Q2	DFCO	Operating Lease Liability Noncurrent Related Party OperatingLeaseLiabilityNoncurrentRelatedParty	1741830	usd
CY2023Q4	us-gaap	Liabilities Liabilities	29357690	usd
CY2023Q2	us-gaap	Liabilities Liabilities	20916279	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90392109	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	90392109	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	88699139	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	88699139	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	471443	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	443478	usd
CY2023Q4	DFCO	Common Stock To Be Issued CommonStockToBeIssued	128925	usd
CY2023Q2	DFCO	Common Stock To Be Issued CommonStockToBeIssued	192925	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	148335488	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	145251822	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151951449	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141729009	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4666	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50848	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3019608	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4109019	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	87941	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	143817	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2931667	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4252836	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26426023	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25169115	usd
CY2023Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5859240	usd
CY2022Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4603878	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9980866	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8776127	usd
CY2023Q4	DFCO	Revenues Related Party RevenuesRelatedParty	218522	usd
CY2022Q4	DFCO	Revenues Related Party RevenuesRelatedParty	649242	usd
	DFCO	Revenues Related Party RevenuesRelatedParty	1114976	usd
	DFCO	Revenues Related Party RevenuesRelatedParty	734760	usd
CY2023Q4	us-gaap	Revenues Revenues	6077762	usd
CY2022Q4	us-gaap	Revenues Revenues	5253120	usd
	us-gaap	Revenues Revenues	11095842	usd
	us-gaap	Revenues Revenues	9510887	usd
CY2023Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4076002	usd
CY2022Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2955132	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8123224	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5311460	usd
CY2023Q4	us-gaap	Gross Profit GrossProfit	2001760	usd
CY2022Q4	us-gaap	Gross Profit GrossProfit	2297988	usd
	us-gaap	Gross Profit GrossProfit	2972618	usd
	us-gaap	Gross Profit GrossProfit	4199427	usd
CY2023Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1018827	usd
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	901721	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2128469	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1369238	usd
CY2023Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6227434	usd
CY2022Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7080077	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12270088	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11937694	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	6227434	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	7080077	usd
	us-gaap	Operating Expenses OperatingExpenses	12270088	usd
	us-gaap	Operating Expenses OperatingExpenses	11937694	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4225674	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4782089	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9297470	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7738267	usd
CY2023Q4	us-gaap	Interest Expense InterestExpense	213960	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	1220603	usd
	us-gaap	Interest Expense InterestExpense	327153	usd
	us-gaap	Interest Expense InterestExpense	1892730	usd
CY2023Q4	us-gaap	Interest Income Operating InterestIncomeOperating	20884	usd
CY2022Q4	us-gaap	Interest Income Operating InterestIncomeOperating	22826	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	40127	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	41895	usd
CY2023Q4	us-gaap	Other Income OtherIncome	-1023079	usd
CY2022Q4	us-gaap	Other Income OtherIncome	-444699	usd
	us-gaap	Other Income OtherIncome	-688699	usd
	us-gaap	Other Income OtherIncome	-106622	usd
CY2023Q4	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	0	usd
CY2022Q4	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	2037712	usd
	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	0	usd
	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	2090978	usd
CY2023Q4	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	1649	usd
CY2022Q4	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-95312	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-5121	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-47595	usd
CY2023Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1214506	usd
CY2022Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	299924	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-980846	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	85926	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-5440180	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-4482165	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-10278316	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-7652341	usd
CY2023Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-39026	usd
CY2022Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-34129	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	46182	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	29633	usd
CY2023Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5479206	usd
CY2022Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4516294	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10232134	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7622708	usd
CY2023Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-33982	usd
	us-gaap	Profit Loss ProfitLoss	-7652341	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	355689	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	348512	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2128469	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1369238	usd
	DFCO	Stock Consideration Issued To Vendor StockConsiderationIssuedToVendor	233000	usd
CY2022Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-69147	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-55876	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	378466	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-5406198	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-4413018	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10222440	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8030807	usd
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89962164	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	84437801	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89120328	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	80721783	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	89962164	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	84437801	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	89120328	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	80721783	shares
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-14953182	usd
CY2022Q3	DFCO	Common Stock Issued For Conversion Of Convertible Notes Accrued Interest And Premium CommonStockIssuedForConversionOfConvertibleNotesAccruedInterestAndPremium	1111397	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	172350	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	467517	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-3170176	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	63762	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-16308332	usd
CY2022Q4	DFCO	Common Stock Issued For Conversion Of Convertible Notes Accrued Interest And Premium CommonStockIssuedForConversionOfConvertibleNotesAccruedInterestAndPremium	336091	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	75459	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	901721	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	-4482165	usd
CY2022Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-34129	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-19511355	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4252836	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	269	usd
CY2023Q3	DFCO	Common Stock Issued Pursuant To Debt Agreement CommonStockIssuedPursuantToDebtAgreement	60000	usd
CY2023Q3	DFCO	Warrants Issued Pursuant To Acquisitions WarrantsIssuedPursuantToAcquisitions	5478	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1109642	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-4838136	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	85208	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	675297	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	70667	usd
CY2023Q4	DFCO	Common Stock Issued Pursuant To Debt Agreement CommonStockIssuedPursuantToDebtAgreement	173000	usd
CY2023Q4	DFCO	Warrants Issued Pursuant To Acquisitions WarrantsIssuedPursuantToAcquisitions	5748	usd
CY2023Q4	DFCO	Common Stock To Be Issued For Private Placement CommonStockToBeIssuedForPrivatePlacement	604000	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1018827	usd
CY2023Q4	us-gaap	Profit Loss ProfitLoss	-5440180	usd
CY2023Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-39026	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2931667	usd
	us-gaap	Profit Loss ProfitLoss	-10278316	usd
	DFCO	Stock Consideration Issued To Vendor StockConsiderationIssuedToVendor	0	usd
	DFCO	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	117005	usd
	DFCO	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	108609	usd
	DFCO	Bad Debt Expense BadDebtExpense	393225	usd
	DFCO	Bad Debt Expense BadDebtExpense	593664	usd
	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	-0	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	191468	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	491151	usd
	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	2090978	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1605336	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-269094	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	863405	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	885299	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2430615	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-705365	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-227523	usd
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	-39995	usd
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	-18149	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	375220	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	195528	usd
	DFCO	Increase Decrease In Longterm Payables IncreaseDecreaseInLongtermPayables	-14995	usd
	DFCO	Increase Decrease In Longterm Payables IncreaseDecreaseInLongtermPayables	-29833	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	5991166	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-253709	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-163849	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2277287	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	0	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	35242	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-398436	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	749378	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3476354	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4911404	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	299355	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	605515	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	385792	usd
	DFCO	Acquisition Of Business Net Of Cash AcquisitionOfBusinessNetOfCash	0	usd
	DFCO	Acquisition Of Business Net Of Cash AcquisitionOfBusinessNetOfCash	70979	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-299355	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-920328	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1854380	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	7320324	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-428924	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-752256	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	1485703	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-1077	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	604000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3515159	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6566991	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-260550	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	735259	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46182	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29633	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	812806	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	772062	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	598438	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1536954	usd
	us-gaap	Interest Paid Net InterestPaidNet	114626	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80C_eus-gaap--NatureOfOperations_zO5pJpRvZgTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt"><b>1.</b></span></td> <td style="text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_82B_zzA2d2wMoD5i">Organization and Nature of Operations</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Moving the world forward takes bold resolve that turns ideas into actions and builds real-time solutions that positively impact people and the planet. Dalrada accelerates positive change for current and future generations by harnessing true potential and developing products and services that become transformative innovations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada Financial Corporation, (“Dalrada”), was incorporated in September 1982 under the laws of the State of California. It was reincorporated in May 1983 under the laws of the State of Delaware and reincorporated again on May 5, 2020, under the laws of the state of Wyoming. Dalrada Financial Corporation trades under the symbol, OTCQB: DFCO.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada has five business divisions: <b>Genefic</b>, <b>Dalrada Climate Technology</b>, <b>Dalrada Precision Manufacturing</b>, <b>Dalrada Technologies </b>and <b>Dalrada Corporate</b>. Within each of these divisions, the Company drives transformative innovation while creating solutions that are sustainable, accessible, and affordable. Dalrada’s global solutions directly address climate change, gaps in the health care industry, and technology needs that facilitate a new era of human behavior and interaction and ensure a bright future for the world around us.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><span style="text-decoration: underline">Genefic (Formerly Dalrada Health)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Genefic delivers advanced health care solutions with dedicated products, services, and systems. From virus and disease screening capabilities to pharmaceutical goods and holistic wellness clinics, When the world needs advanced health care, Genefic delivers with ingenuity, accessibility, and affordability. This specialized division is committed to developing key health products, lifesaving medications and building comprehensive systems to increase capability, strive to keep people healthy with the goals of improving their quality of life and increasing their longevity– on a global level.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Boost Diagnostics</b>- Boost Diagnostics (formerly Empower Genomics and Genefic Diagnostics) is Dalrada’s wholly owned diagnostic laboratory subsidiary which processes molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus. Boost Diagnostics has built up and maintained the testing capacity to handle surges in COVID-19 testing demands. Boost Diagnostics also offers genetic testing capabilities including Pharmacogenomics, Nutraceutical, Nutrition/Diet DNA and Exercise/Fitness DNA tests.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Pala Diagnostics (“Pala”)</b>- Pala was a joint venture diagnostic laboratory entity which processed both molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus. Pala was no longer an operational entity as of June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Genefic Wellness Group (“Genefic Wellness”)</b>- Genefic Wellness (formerly Solas Corp.) manages and oversees wellness clinics throughout Southern California including the Sòlas Rejuvenation + Wellness clinics (“Sòlas”). Through advanced medical techniques and modern technology, Sòlas delivers a clinical experience that helps men and woman live their best life, whether it’s through simple cosmetic procedures, pain-reducing practices, or anti-aging therapies. Through its three locations, Sòlas prides itself on its dedicated service-focused, health-first approach. Its wellness & rejuvenation clinics deliver with a focus on regenerative therapies, IV and injection services, cosmetic enhancements amongst a myriad of additional health centric services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Achieve Wellness-</b> Achieve Wellness is a full-service consulting company which helps businesses incorporate effective weight loss and wellness programs. Achieve Wellness’ services include the integration of cutting-edge technologies, products, and services specific to weight loss strategies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>International Health Group (“IHG”)</b>- IHG provides highly trained nursing and medical assistants for hospitals and home health facilities since 2006. IHG Medical Assistant programs include Certified Nursing Assistant (“CNA") and Home Health Aide (“HHA”) training and the fast-track 22-Day CNA Certification Program at its state-approved testing facility.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Pacific Stem Cells (“PSC”)</b>- PSC markets and sells traditional biologics and human cells, tissues, and cellular and tissue-based products (HCT/Ps).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Genefic Specialty Pharmacy (“Genefic Pharmacy”)</b>- Genefic Pharmacy (formerly Watson Rx Solutions) is an Alabama-based pharmacy with more than 30 years of experience in the retail medical and pharmaceutical industries. Genefic Pharmacy specializes in providing expert care and managing disease states through comprehensive prescription management, education, nursing, and total health solutions. Genefic Pharmacy maintains pharmacy licenses in all 50 States including Washington D.C.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><span style="text-decoration: underline">Dalrada Climate Technology (formerly Dalrada Energy Services)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Dalrada Climate Technology (“DCT”) is a segment which incapsulates energy services and state-of-the-art technology within the climate sustainability space. DCT employs next-generation technology and services which enhances clean energy efforts while reducing the world’s carbon footprint. As a premier industrial heat pump manufacturer, Dalrada delivers innovation and efficiency, building solutions that reduce energy consumption and minimize carbon footprints, increase operational efficiencies, meet environmental, social, and governance (ESG) goals, and lower energy costs for clients. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Likido Ltd. (“Likido”)</b>- Likido is an international engineering company developing advanced solutions for the harvesting and recycling of energy. Using its novel, heat pump systems (patent pending), Likido is working to revolutionize the renewable energy sector with the provision of innovative modular process technologies to maximize the capture and reuse of thermal energy for integrated heating and cooling applications. With uses across industrial, commercial and residential sectors, Likido provides cost savings and minimized carbon emissions across global supply chains. Likido's technologies enable the effective recovery and recycling of process energy, mitigating against climate change and expected enhancement of quality of life through the provision of low-carbon heating and cooling systems. Likido’s products currently include the DCT One Series Heat Pumps (formerly Likido®ONE) and DCT Cryo Chiller.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">During the prior year, the U.S. Government selected DCT One Series high-performance, low-carbon heat pump for real-world testing in a prestigious clean energy program. The implementation of the DCT One Series testing is still in process. The expected positive results should not only increase market acceleration and adoption within the federal government acceptance of groundbreaking eco-friendly technology but should also accelerate adoption within the commercial building industry.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Technology Limited (“DTL”)- </b>DTL is a holding company for all European based Dalrada Precision entities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Technology Spain L.T. (“DTS”)- </b>DTS was established as a Spanish subsidiary of DTL for the expansion of the manufacturing and sale of the DCT One Series and DCT Cryo Chiller throughout Europe.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Energy Services (“DES”)</b>- DES provides end-to-end comprehensive energy service solutions in a robust commercial capacity. DES helps organizations meet ESG goals and standards while mitigating negative environmental impacts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Bothof Brothers Construction (“Bothof”)</b>- Bothof is a licensed general contractor which provides a wide range of development, construction and design capabilities and expertise throughout the United States. Through Bothof’s extensive experience in construction and contracting, the DES division can provide a myriad of additional services to its private and public works customers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Financial Corporation Morocco (“DFCM”)- </b>DFCM was established as a Moroccan subsidiary of Dalrada to conduct energy service solutions within the country of Morocco. Dalrada owns a <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DalradaFinancialCorporationMoroccoMember_zQGrNS2ogAI6">33</span>% equity interest in DFCM.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><span style="text-decoration: underline">Dalrada Precision Manufacturing</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Dalrada Precision Manufacturing creates total manufacturing solutions that start with the design and development of high-quality machine parts and components, and end with an efficient global supply chain. This specialized business division can meet today’s high demands and solves industry challenges. Dalrada Precision Manufacturing is confident that it redefines the critical quality of the world’s top components and responds with in-house research, design, engineering, and distribution through a highly reliable global supply chain and improved time-to-market capabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Precision Parts (“Precision”)</b>- Precision extends the client its engineering and operations team by helping devise unique manufacturing solutions tailored to their products. Dalrada Precision can enter at any stage of the product lifecycle from concept and design to mass production and logistics.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Deposition Technologies (“DepTec”)</b>- DepTec designs, develops, manufactures, and services chemical vapor and physical vapor deposition systems for the microchip and semiconductor industries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">DepTec has built an impressive catalogue of precision OEM parts for PVD (<span style="background-color: white">Physical vapor deposition)</span> systems and the Company’s refurbished systems which allows clients the option of purchasing the same model of system they’ve been using for decades –but with significant upgrades and improved efficiencies. Older systems can now operate more reliably with additional control and monitoring plus longer lifespans. DepTec also has its own PVD and CVD (Chemical Vapor Deposition) systems, EVOS-PVD and EVOS -CVD, which deposits metals and non-metals for microchips used in almost every standard and specialized microdevices made today and in the future. These systems can produce a superior film layer utilized in rugged high-stress environment designs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Ignite I.T. (“Ignite”)</b>- Ignite is a manufacturer and seller of eco-friendly deep cleaners, parts washers and degreasers that are specially formulated to lift hydrocarbon-based dirt and grease from virtually all surfaces with minimal effort. Ignite products are non-flammable, non-corrosive, non-toxic, butyl-free, water-based, and leave a light citrus scent. Ignite is developed for all surfaces suitable for water and meets or exceed the most stringent industry-testing specifications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><span style="text-decoration: underline">Dalrada Technologies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada Technologies has worked with some of the world’s most recognizable companies, providing digital engineering for cutting-edge software systems and offering a host of robust digital services. This business division connects the world with integrated technology and innovative solutions, delivering advanced capabilities and error-free results. Dalrada Technologies creates digital products with expert computer information technology and software engineering services for a variety of technical industries and clients in both B2B and B2C environments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Prakat (“Prakat”)</b>- Prakat is an ISO 9001-certified company that provides end-to-end technology services across various industries, improving the value chain. The Company specializes in test engineering, accessibility engineering, product engineering, application modernization, billing and revenue management, CRM, and block chain. Prakat provides global customers with software and technology solutions specializing in Test Engineering, Accessibility Engineering, Product Engineering and Application Modernization.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Dalrada Corporate</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada Corporate covers the activities which support the entire suite of Dalrada subsidiaries. Dalrada Corporate includes the areas of administration, finance, human resources, legal advice, information technology, and marketing. It also contains executive management and shareholder-related services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">Liquidity and Going Concern</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These unaudited interim condensed consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the continued financial support from related parties, its ability to identify future investment opportunities, obtain the necessary debt or equity financing, and generate profitable operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zZgHMRvQxc4c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="font-size: 10pt"><span id="xdx_861_zU2sQC3kwO4">Use of Estimates</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of these unaudited interim condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the revenue, valuation of inventory, valuation of acquired assets and liabilities, variables used in the computation of share-based compensation, litigation, contingent consideration, and evaluation of goodwill and intangible assets for impairment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zIdpe6gltsM4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-size: 10pt">(d)</span></td> <td style="text-align: justify"><span style="font-size: 10pt"><span id="xdx_86C_zgHT0Dngpqu">Concentrations of Credit Risk</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, as well as accounts receivable. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">When estimating its allowance for credit losses related to revenues from Covid Testing and pharmacy sales, the Company differentiates its receivables based on the following customer types: healthcare insurers, government payers, and cash payers. Additionally, the Company applies assumptions and judgments for assessing collectability and determining net revenues and accounts receivable from its customers. Management considers various historical collection factors for assessing collectability and determining net revenues and accounts receivable from our customers which include the period that the receivables have been outstanding, history of payment amounts, status of collections due, and applicable statutes of limitations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the six months ended December 31, 2023 and December 31, 2022, healthcare insurers, government payers and OTC pharmaceutical sales accounted for over <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--HealthcareInsurersGovernmentPayersAndOTCPharmaceuticalSalesMember_zyYsD0TEc18l" title="Concentrations risk, percentage">49</span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--HealthcareInsurersGovernmentPayersAndOTCPharmaceuticalSalesMember_zbsbMDWdEFSb" title="Concentrations risk, percentage">38</span>% of total revenues, respectively. Also, healthcare insurers, government payers and OTC pharmaceutical sales amounted to total revenues of $<span id="xdx_90E_eus-gaap--Revenues_pp0p0_c20230701__20231231__srt--ProductOrServiceAxis__custom--HealthcareInsurersGovernmentPayersAndOTCPharmaceuticalSalesMember_zLE70vvtq8Ud" title="Revenues">5,502,854</span> and $<span id="xdx_905_eus-gaap--Revenues_pp0p0_c20220701__20221231__srt--ProductOrServiceAxis__custom--HealthcareInsurersGovernmentPayersAndOTCPharmaceuticalSalesMember_zJJZwGaSOvz9" title="Revenues">1,710,799</span> for the six months ended December 31, 2023 and 2022, respectively. The accounts receivable related to both healthcare insurers and government payers is $<span id="xdx_909_eus-gaap--AccountsReceivableNet_iI_pp0p0_c20231231__srt--ProductOrServiceAxis__custom--HealthcareInsurersAndGovernmentPayersMember_za3VGFrrvb72" title="Accounts receivable">3,585,109</span> and $<span id="xdx_902_eus-gaap--AccountsReceivableNet_iI_pp0p0_c20230630__srt--ProductOrServiceAxis__custom--HealthcareInsurersAndGovernmentPayersMember_z69ckvXRD8Rg" title="Accounts receivable">1,499,415</span> as of December 31, 2023 and June 30, 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2023 and June 30, 2023, $<span id="xdx_90A_eus-gaap--AccountsReceivableNet_c20231231__srt--ProductOrServiceAxis__custom--LikidoUnitsMember_pp0p0" title="Accounts receivable">618,031</span> and $<span id="xdx_908_eus-gaap--AccountsReceivableNet_c20230630__srt--ProductOrServiceAxis__custom--LikidoUnitsMember_pp0p0" title="Accounts receivable">829,239</span> is owed by customers from the sale of Likido units, respectively.</p>
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	4402394	usd
CY2023Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	4285389	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2603494	usd
CY2023Q4	DFCO	Change In Fair Value Of Contingent Consideration1 ChangeInFairValueOfContingentConsideration1	440810	usd
	DFCO	Change In Fair Value Of Contingent Consideration1 ChangeInFairValueOfContingentConsideration1	117005	usd
CY2023Q4	DFCO	Contingent Consideration ContingentConsideration	4402394	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	433556	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	usd
CY2023Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	usd
CY2023Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6077762	usd
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5253120	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11095842	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9510887	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	5488915	usd
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	4453104	usd
CY2023Q4	DFCO	Accounts Receivable Net Related Parties Current AccountsReceivableNetRelatedPartiesCurrent	928648	usd
CY2023Q2	DFCO	Accounts Receivable Net Related Parties Current AccountsReceivableNetRelatedPartiesCurrent	752348	usd
CY2023Q4	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	20141	usd
CY2023Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	41722	usd
CY2023Q4	DFCO	Longterm Receivables Related Parties Current LongtermReceivablesRelatedPartiesCurrent	1155479	usd
CY2023Q2	DFCO	Longterm Receivables Related Parties Current LongtermReceivablesRelatedPartiesCurrent	1173893	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	938823	usd
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	1337259	usd
CY2023Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4076002	usd
CY2022Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2955132	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8123224	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5311460	usd
CY2023Q4	us-gaap	Advertising Expense AdvertisingExpense	65000	usd
CY2022Q4	us-gaap	Advertising Expense AdvertisingExpense	92000	usd
	us-gaap	Advertising Expense AdvertisingExpense	106000	usd
	us-gaap	Advertising Expense AdvertisingExpense	201000	usd
CY2023Q4	us-gaap	Share Based Compensation ShareBasedCompensation	1018827	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	901721	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2128469	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1369238	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	177094	usd
CY2023Q4	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	94371	usd
CY2022Q4	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	133435	usd
CY2023Q4	DFCO	Notes Payable Related Parties NotesPayableRelatedParties	4834971	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1039674	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	658175	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1120243	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	708007	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	409926	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	712510	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2569843	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2078692	usd
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1866443	usd
CY2023Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1448556	usd
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	351284	usd
CY2023Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	208689	usd
CY2023Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	414648	usd
CY2023Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	426162	usd
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	0	usd
CY2023Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	249613	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2632375	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2333020	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1009364	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	856938	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1623011	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1476082	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	152426	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	171418	usd
CY2023Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	127759	usd
CY2022Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	82360	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4350891	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4350891	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-492805	usd
	DFCO	Finite Lived Intangible Assets Accumulated Amortization Additions FiniteLivedIntangibleAssetsAccumulatedAmortizationAdditions	-203263	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-696068	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3654823	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	203263	usd
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	112789	usd
CY2023Q2	DFCO	Notes Payable Related Parties NotesPayableRelatedParties	1900083	usd
CY2023Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	14182	usd
CY2023Q4	DFCO	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	0	usd
CY2023Q4	DFCO	Notes Payable Related Parties Noncurrent1 NotesPayableRelatedPartiesNoncurrent1	4834971	usd
CY2023Q4	DFCO	Notes Payable Related Parties NotesPayableRelatedParties	4834971	usd
CY2023Q2	DFCO	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	251605	usd
CY2023Q2	DFCO	Notes Payable Related Parties Noncurrent1 NotesPayableRelatedPartiesNoncurrent1	1648478	usd
CY2023Q2	DFCO	Notes Payable Related Parties NotesPayableRelatedParties	1900083	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	439562	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	439562	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	2414936	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	1011395	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	2854498	usd
CY2023Q2	us-gaap	Notes Payable NotesPayable	1450957	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	600000	usd
	DFCO	Redemption Premium In Cash RedemptionPremiumInCash	0	usd
	DFCO	Redemption Premium In Cash RedemptionPremiumInCash	120000	usd
	DFCO	Redemption Premium In Stock RedemptionPremiumInStock	0	usd
	DFCO	Redemption Premium In Stock RedemptionPremiumInStock	120000	usd
	DFCO	Accretion Interest Expense AccretionInterestExpense	0	usd
	DFCO	Accretion Interest Expense AccretionInterestExpense	180000	usd
	DFCO	Redeemed Cash RedeemedCash	0	usd
	DFCO	Redeemed Cash RedeemedCash	600000	usd
	DFCO	Redeemed Debentures RedeemedDebentures	0	usd
	DFCO	Redeemed Debentures RedeemedDebentures	300000	usd
CY2023Q4	DFCO	Revenues Related Party RevenuesRelatedParty	218522	usd
CY2022Q4	DFCO	Revenues Related Party RevenuesRelatedParty	649242	usd
	DFCO	Revenues Related Party RevenuesRelatedParty	1114976	usd
	DFCO	Revenues Related Party RevenuesRelatedParty	734760	usd
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.45
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.59
CY2022Q1	DFCO	Fair Value Of Options Granted FairValueOfOptionsGranted	1338644	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.45
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	250000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.15
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.08
CY2023Q2	DFCO	Fair Value Of Options Granted FairValueOfOptionsGranted	2143402	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.10
CY2023Q2	DFCO	Fair Value Of Options Granted FairValueOfOptionsGranted	47408	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.08
CY2023Q3	DFCO	Fair Value Of Options Granted FairValueOfOptionsGranted	2064699	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12025000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M25D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	33426134	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.29
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	45451134	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.33
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M29D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	16111000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.13
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	61562134	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.28
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M20D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	33243708	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.34
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y2M26D
	us-gaap	Share Based Compensation ShareBasedCompensation	2128469	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1369238	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5318203	usd
CY2023Q4	us-gaap	Revenues Revenues	6077762	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4225674	usd
CY2022Q4	us-gaap	Revenues Revenues	5253120	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4782089	usd
	us-gaap	Revenues Revenues	11095842	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9297470	usd
	us-gaap	Revenues Revenues	9510887	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7738267	usd
	us-gaap	Revenues Revenues	11095842	usd
	us-gaap	Revenues Revenues	9510887	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2569843	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2078692	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1623011	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1476082	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	764412	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1441424	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1353474	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1234880	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	432131	usd
CY2023Q4	DFCO	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	32627	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5258948	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	469796	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4789152	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M21D
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M2D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0684	pure
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0674	pure

Files In Submission

Name	View Source	Status
0001683168-24-000995-index-headers.html	Edgar Link	pending
0001683168-24-000995-index.html	Edgar Link	pending
0001683168-24-000995.txt	Edgar Link	pending
0001683168-24-000995-xbrl.zip	Edgar Link	pending
dalrada_ex3101.htm	Edgar Link	pending
dalrada_ex3102.htm	Edgar Link	pending
dalrada_ex3201.htm	Edgar Link	pending
dalrada_ex3202.htm	Edgar Link	pending
dalrada_i10q-123123.htm	Edgar Link	pending
dfco-20231231.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
dfco-20231231_cal.xml	Edgar Link	unprocessable
dfco-20231231_def.xml	Edgar Link	unprocessable
dfco-20231231_lab.xml	Edgar Link	unprocessable
dfco-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
dalrada_i10q-123123_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DFCO
DALRADA FINANCIAL CORP Stock $dfco

2024 Q1 Form 10-Q Financial Statement

#000168316824000995 Filed on February 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFCO DALRADA FINANCIAL CORP Stock $dfco

2024 Q1 Form 10-Q Financial Statement

#000168316824000995 Filed on February 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFCO
DALRADA FINANCIAL CORP Stock $dfco